Company intelligence / Profile preview

VeraMorph

Norwood, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Oral fulvestrant formulation demonstrated 55% improved tumor growth inhibition and 20 times higher plasma concentrations vs. injectable in preclinical studies; well-tolerated; advancing to IND-enabling studies with NCI SBIR Fast Track grant.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

VER001

Preclinical

Partnerships

Undisclosed top 20 global oncology company (feasibility study)

Beyond the preview

Go deeper on VeraMorph.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VeraMorph.

Explore the full profile